This program aims to develop anti-CD123 × CD3 therapeutic Bispecific Antibody for immuno-oncology.
From previous knowledge, T cell-redirecting bispecific antibodies have demonstrated impressive achievements in cancer immunotherapy, including chimeric antigen receptor T cells, immune checkpoint inhibitors and T cell-redirecting bispecific antibodies (TRBAs). In particular, by recognizing two different epitopes on T cells and cancer cells, Bispecific Antibody is attracting increasing attention as an innovative strategy in cancer immunotherapy. Here we propose an innovative a novel combination, CD123 bispecific T-cell engager (BiTE) for the next AML treatment.
Interleukin-3 receptor alpha, known as Cluster of Differentiation 123 (CD123), consists a chain of specific low-affinity alpha and a signal transducing beta subunit joined by the interleukin-3 receptor. CD123 is expressed on myeloid progenitor cells, plasmacytoid dendritic cells, monocytes, and basophils. Binding of IL-3 triggers a set of CD123 pathway, including heterodimerization, differentiation and proliferation of hematopoietic progenitor cells by phosphorylation of Janus kinase, activation of PI3 kinase, and up-regulation of anti-apoptotic proteins. CD123 is significantly overexpressed in acute myeloid leukemia (AML) patients, hence, identified as a novel target of AML.
Fig.1 Antibody-based therapeutic strategies for AML.
Here are some published data about CD123 × CD3 working as a potential target for cancer immunotherapy.
Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-CD123 × CD3 therapeutic Bispecific Antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to working with you in the near future.
For Research Use Only | Not For Clinical Use
Download our brochure